research Molecular Interactions of New Pregnenedione Derivatives
The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
Search
for
Sort by
Research
300-330 / 1000+ results research Editorial Comment
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
research Microarray analysis reveals distinct RNA expression profiles in endothelial progenitor cells exposed to pro-inflammatory environment or oxidized LDL
Different cells affect hair follicle blood vessels, endothelial cells react differently to inflammation and oxidized fats, and prasugrel better protects heart vessels during a procedure than clopidogrel.
research Novel type 1 5a-reductase Inhibitors with Antiproliferative Potential on LNCaP cells
New compounds may help treat prostate cancer by reducing cell growth.
research Editorial comment 1
Finasteride may reduce prostate cancer risk.
research A New Look at the 5á-Reductase Inhibitor Finasteride
Finasteride, a medication, is being re-evaluated for its effects and uses.
research Steroid 5α-Reductase Inhibitors
New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
research The use of saw palmetto versus finasteride for the treatment of prostatitis/chronic pelvic pain syndrome
research Simultaneous Estimation of Finasteride and Tamsulosin Hydrochloride in Combined Dosage Forms by RP-HPLC-PDA Method
The method accurately measures Tamsulosin and Finasteride in medication and is suitable for regular quality checks.
research Finasteride
Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
research Dutasteride
Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.
research SAT-279 The Effect of Chronic 5-alpha Reductase Inhibition on Clinically Apparent and Silent Cardiovascular Events
Finasteride lowers cholesterol but doesn't reduce heart-related events.
research Erectile dysfunction from mechanisms to medicines with a focus on the application of topical Minoxidil
research Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment
Long-term use of dutasteride can cause permanent erectile dysfunction in rats.
research Predstanormix Duo – a new domestic combination drug for the treatment of lower urinary tract dysfunction symptoms associated with BPH.
Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
research DIHYDROTESTOSTERONE AND THE PROSTATE: THE SCIENTIFIC RATIONALE FOR 5α-REDUCTASE INHIBITORS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.
research Role of 5α-reductase inhibitors in benign prostatic diseases
5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
research Medikamentöse Therapie des benignen Prostatasyndroms (BPS)
Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
research In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors
The new compounds may be more effective and cheaper than current treatments for conditions like baldness.
research LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1.
LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Role of 5 alpha-reductase inhibitors in the management of prostate cancer
5 alpha-reductase inhibitors like finasteride may lower prostate cancer risk and improve cancer screening.
research MINOXIDIL INDUCED PLEURO-PERICARDIAL EFFUSION IN END-STAGE RENAL DISEASE
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research No increased risk of CV events with dutasteride vs finasteride
Dutasteride and finasteride have equal safety for treating BPH without increased heart risk.
research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
research Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
Tamsulosin with Serenoa repens is as effective as with 5-alpha-reductase inhibitors but causes fewer side effects.
research Direct Vasodilators and Sympatholytic Agents
Direct vasodilators and sympatholytic agents are still useful for certain conditions despite being less common due to side effects and newer drugs.
research Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia
Ezetimibe effectively reduces prostate size in cases of benign prostatic hyperplasia.
research Eficacia de la combinación de doxazosina y finasterida en la hipertrofia benigna de próstata
Combining doxazosin and finasteride is more effective for managing benign prostatic hyperplasia than using either drug alone.